Please assess the completion status of the following clinical trial:

Trial Title: Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female participants 2 aged 18-65 years 3 BMI 18.0-35.0 kg/m2, maximum weight 100 kg 4 in good health, as determined by: 4a medical history, 4b physical examination, 4c vital signs assessment, 4d 12-lead ECG 4e clinical laboratory evaluations 5 provision of informed consent and abide by study restrictions~Exclusion Criteria:~1. not willing to abide by contraception restrictions~2. donated blood in previous 3 months, plasma previous 7 days, platelets previous 6 weeks~3. consumption \>14 units of alcohol/week~4. tobacco smoking~5. concomitant medication, apart from treatments for mild asthma, eczema, contraception, paracetamol~6. herbal remedies~7. history of anaphylaxis, drug allergy, clinically significant atopic condition as determined by Investigator~8. clinically significant medical history, as determined by the Investigator~9. positive hepatitis, HIV serology~10. live vaccine in previous 3 months, Covid-19 vaccine prior 14 days~11. Participants who, in the opinion of the Investigator, should not participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AWZ1066S (Type: EXPERIMENTAL): AWZ1066S~Part A Cohort A1- 100mg single dose Cohort A2- 200mg single dose Cohort A3- 400mg single dose Cohort A4- 800mg fasted single dose and 800mg fed single dose Cohort A5- 1200mg single dose Cohort A6- 1600mg single dose~The doses for part B will be selected following review of data from Part A. Cohort B1- AWZ1066S once daily for 7 days Cohort B2- AWZ1066S once daily for 7 days Cohort B3- AWZ1066S once daily for 7 days Cohort B4- AWZ1066S once daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo~Cohort A1- equivalent placebo single dose Cohort A2- equivalent placebo single dose Cohort A3- equivalent placebo single dose Cohort A4- equivalent placebo fasted single dose and equivalent placebo fed single dose Cohort A5- equivalent placebo single dose Cohort A6- equivalent placebo single dose~The doses for part B will be selected following review of data from Part A. Cohort B1- equivalent placebo once daily for 7 days Cohort B2- equivalent placebo once daily for 7 days Cohort B3- equivalent placebo once daily for 7 days Cohort B4- equivalent placebo once daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).